Literature DB >> 3276446

Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients.

C De Simone1, G Delogu, G Corbetta.   

Abstract

The therapeutic use of iv immunoglobulins of the G class in association with antibiotics in patients with severe sepsis is reported. As compared to the randomized control group of patients treated with antibiotics alone, patient survival was only slightly improved (from 25% to 42%; NS); however, the defervescence time was significantly shorter (10 vs. 16 days), and a greater percentage of microbiologically positive cultures became negative (40% vs. 8%; p less than .01). The percentage of days on antibiotic treatment during ICU hospitalization was consequently reduced (38% vs. 95%; p less than .01). The therapeutic use of iv immunoglobulin G is discussed in terms of antibody substitution and modulation of the immune system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276446     DOI: 10.1097/00003246-198801000-00005

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).

Authors:  Osamu Nishida; Hiroshi Ogura; Moritoki Egi; Seitaro Fujishima; Yoshiro Hayashi; Toshiaki Iba; Hitoshi Imaizumi; Shigeaki Inoue; Yasuyuki Kakihana; Joji Kotani; Shigeki Kushimoto; Yoshiki Masuda; Naoyuki Matsuda; Asako Matsushima; Taka-Aki Nakada; Satoshi Nakagawa; Shin Nunomiya; Tomohito Sadahiro; Nobuaki Shime; Tomoaki Yatabe; Yoshitaka Hara; Kei Hayashida; Yutaka Kondo; Yuka Sumi; Hideto Yasuda; Kazuyoshi Aoyama; Takeo Azuhata; Kent Doi; Matsuyuki Doi; Naoyuki Fujimura; Ryota Fuke; Tatsuma Fukuda; Koji Goto; Ryuichi Hasegawa; Satoru Hashimoto; Junji Hatakeyama; Mineji Hayakawa; Toru Hifumi; Naoki Higashibeppu; Katsuki Hirai; Tomoya Hirose; Kentaro Ide; Yasuo Kaizuka; Tomomichi Kan'o; Tatsuya Kawasaki; Hiromitsu Kuroda; Akihisa Matsuda; Shotaro Matsumoto; Masaharu Nagae; Mutsuo Onodera; Tetsu Ohnuma; Kiyohiro Oshima; Nobuyuki Saito; So Sakamoto; Masaaki Sakuraya; Mikio Sasano; Norio Sato; Atsushi Sawamura; Kentaro Shimizu; Kunihiro Shirai; Tetsuhiro Takei; Muneyuki Takeuchi; Kohei Takimoto; Takumi Taniguchi; Hiroomi Tatsumi; Ryosuke Tsuruta; Naoya Yama; Kazuma Yamakawa; Chizuru Yamashita; Kazuto Yamashita; Takeshi Yoshida; Hiroshi Tanaka; Shigeto Oda
Journal:  Acute Med Surg       Date:  2018-02-05

3.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 4.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

5.  Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults.

Authors:  Kevin B Laupland
Journal:  Can J Infect Dis       Date:  2002-03

6.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

7.  The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).

Authors:  Osamu Nishida; Hiroshi Ogura; Moritoki Egi; Seitaro Fujishima; Yoshiro Hayashi; Toshiaki Iba; Hitoshi Imaizumi; Shigeaki Inoue; Yasuyuki Kakihana; Joji Kotani; Shigeki Kushimoto; Yoshiki Masuda; Naoyuki Matsuda; Asako Matsushima; Taka-Aki Nakada; Satoshi Nakagawa; Shin Nunomiya; Tomohito Sadahiro; Nobuaki Shime; Tomoaki Yatabe; Yoshitaka Hara; Kei Hayashida; Yutaka Kondo; Yuka Sumi; Hideto Yasuda; Kazuyoshi Aoyama; Takeo Azuhata; Kent Doi; Matsuyuki Doi; Naoyuki Fujimura; Ryota Fuke; Tatsuma Fukuda; Koji Goto; Ryuichi Hasegawa; Satoru Hashimoto; Junji Hatakeyama; Mineji Hayakawa; Toru Hifumi; Naoki Higashibeppu; Katsuki Hirai; Tomoya Hirose; Kentaro Ide; Yasuo Kaizuka; Tomomichi Kan'o; Tatsuya Kawasaki; Hiromitsu Kuroda; Akihisa Matsuda; Shotaro Matsumoto; Masaharu Nagae; Mutsuo Onodera; Tetsu Ohnuma; Kiyohiro Oshima; Nobuyuki Saito; So Sakamoto; Masaaki Sakuraya; Mikio Sasano; Norio Sato; Atsushi Sawamura; Kentaro Shimizu; Kunihiro Shirai; Tetsuhiro Takei; Muneyuki Takeuchi; Kohei Takimoto; Takumi Taniguchi; Hiroomi Tatsumi; Ryosuke Tsuruta; Naoya Yama; Kazuma Yamakawa; Chizuru Yamashita; Kazuto Yamashita; Takeshi Yoshida; Hiroshi Tanaka; Shigeto Oda
Journal:  J Intensive Care       Date:  2018-02-02

Review 8.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

9.  Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial.

Authors:  Marta O Soares; Nicky J Welton; David A Harrison; Piia Peura; Manu Shankar-Hari; Sheila E Harvey; Jason Madan; Anthony E Ades; Kathryn M Rowan; Stephen J Palmer
Journal:  Crit Care       Date:  2014-12-01       Impact factor: 9.097

10.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830].

Authors:  Simru Tugrul; Perihan Ergin Ozcan; Ozkan Akinci; Yalcin Seyhun; Atahan Cagatay; Nahit Cakar; Figen Esen
Journal:  Crit Care       Date:  2002-05-14       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.